World Heart Federation, Daiichi Sankyo and Lilly Partner to Improve Cardiovascular Health
March 30 2009 - 11:01PM
PR Newswire (US)
ORLANDO, Fla., March 31 /PRNewswire/ -- The World Heart Federation,
Daiichi Sankyo Company, Limited (TSE:4568) and Eli Lilly and
Company (NYSE: LLY) announced today that they have partnered to
improve cardiovascular health internationally. The organizations
made the announcement at the 58th Annual Scientific Session of the
American College of Cardiology in Orlando, Florida. An estimated
17.5 million people died from cardiovascular disease in 2005,
representing 30 percent of all global deaths, making it a
significant public health concern.(1) Through this collaboration,
Daiichi Sankyo and Lilly will reinforce the World Heart
Federation's efforts addressing the challenges that result from a
cardiac event, such as a heart attack or stent placement. In
particular, the organizations will work together in emphasizing the
importance of a heart healthy lifestyle and adherence to
medications for acute coronary syndrome (ACS) patients. "We find
that people who have experienced a cardiac event often struggle to
cope with the physical and emotional impact," said Pekka Puska,
President of the World Heart Federation. "This collaboration will
support patients in making the lifestyle changes that are critical
during the recovery process and beyond." Daiichi Sankyo and Lilly
will support activities stemming from the World Heart Federation's
2009 World Heart Day, scheduled to take place on Sunday, September
27 with a focus on workplace wellness. About ACS Acute coronary
syndrome (ACS) is an umbrella term that includes unstable angina
(chest pain) and myocardial infarction (heart attack). ACS is
ultimately the result of coronary heart disease, which is the most
severe among cardiovascular diseases. About the World Heart
Federation The World Heart Federation is a nongovernmental
organization based in Geneva Switzerland dedicated to the
prevention and control of heart disease and stroke, with a focus on
low- and middle-income countries. It is comprised of 195 member
societies of cardiology and heart foundations from over 100
countries covering the regions of Asia-Pacific, Europe, East
Mediterranean, the Americas and Africa. For further information
visit: http://www.world-heart-federation.org/. About Daiichi Sankyo
A global pharma innovator, Daiichi Sankyo Co., Ltd., was
established in 2005 through the merger of two leading Japanese
pharmaceutical companies. This integration created a more robust
organization that allows for continuous development of novel drugs
that enrich the quality of life for patients around the world.
Areas of primary focus for Daiichi Sankyo's research and
development are thrombotic disorders, malignant neoplasm, diabetes
mellitus, and autoimmune disorders. Equally important to the
company are hypertension, hyperlipidemia or atherosclerosis and
bacterial infections. For more information, visit
http://www.daiichisankyo.com/. About Eli Lilly and Company Lilly, a
leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical
products by applying the latest research from its own worldwide
laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides
answers -- through medicines and information -- for some of the
world's most urgent medical needs. (1) World Health Organization.
Cardiovascular diseases. Fact Sheet No. 317. February 2007. (Logo:
http://www.newscom.com/cgi-bin/prnh/20090331/CL90914LOGO ) (Logo:
http://www.newscom.com/cgi-bin/prnh/20061120/DSLLOGO )
http://www.newscom.com/cgi-bin/prnh/20090331/CL90914LOGO
http://www.newscom.com/cgi-bin/prnh/20061120/DSLLOGODATASOURCE: Eli
Lilly and Company CONTACT: Charanjit K. Jagait, World Heart
Federation, +41 22 807 03 34 (office); Carole Copeland, Eli Lilly
and Company, +1-317-277-3661 (office), +1-317-610-6196 (cell);
Kimberly Wix, Daiichi Sankyo, +1-973-695-8338 (office),
+1-908-656-5447 (cell)
Copyright